Formulation Reason 4 O O
which Reason 4 O O
was Reason 4 O O
developed Reason 4 O O
by Reason 4 O O
the Reason 4 O O
Central Reason 4 O O
Council Reason 4 O O
for Reason 4 O O
Research Reason 4 O O
in Reason 4 O O
Ayurvedic Reason 4 O O
Sciences Reason 4 O O
(CCRAS), Reason 4 O O
the Reason 4 O O
apex Reason 4 O O
body Reason 4 O O
for Reason 4 O O
research Reason 4 O O
in Reason 4 O O
Ayurveda Reason 4 O O
under Reason 4 O O
the Reason 4 O O
Ministry Reason 4 O O
of Reason 4 O O
Ayush, Reason 4 O O
for Reason 4 O O
management Reason 4 O O
of Reason 4 O O
Malaria. Reason 4 O O
This Reason 4 O O
drug Reason 4 O O
was Reason 4 O O
repurposed Reason 4 O O
as Reason 4 O O
the Reason 4 O O
ingredients Reason 4 O O
showed Reason 4 O O
notable Reason 4 O O
antiviral, Reason 4 O O
immune-modulator Reason 4 O O
and Reason 4 O O
antipyretic Reason 4 O O
properties. Reason 4 O O
The Reason 4 O O
in-silico Reason 4 O O
study Reason 4 O O
done Reason 4 O O
on Reason 4 O O
AYUSH-64 Reason 4 O O
showed Reason 4 O O
that Reason 4 O O
about Reason 4 O O
35 Reason 4 O O
out Reason 4 O O
of Reason 4 O O
36 Reason 4 O O
of Reason 4 O O
its Reason 4 O O
Phyto-constituents Reason 4 O O
have Reason 4 O O
high Reason 4 O O
binding Reason 4 O O
affinity Reason 4 O O
against Reason 4 O O
COVID-19 Reason 4 O O
virus. Reason 4 O O
The Reason 4 O O
formulation Reason 4 O O
has Reason 4 O O
also Reason 4 O O
shown Reason 4 O O
very Reason 4 O O
promising Reason 4 O O
results Reason 4 O O
in Reason 4 O O
Influenza Reason 4 O O
like Reason 4 O O
illness. Reason 4 O O
With Reason 4 O O
the Reason 4 O O
scientific Reason 4 O O
evidence Reason 4 O O
generated Reason 4 O O
from Reason 4 O O
06 Reason 4 O O
clinical Reason 4 O O
studies Reason 4 O O
across Reason 4 O O
India, Reason 4 O O
AYUSH-64 Reason 4 O O
has Reason 4 O O
been Reason 4 O O
identified Reason 4 O O
as Reason 4 O O
a Reason 4 O O
potential Reason 4 O O
adjunct Reason 4 O O
to Reason 4 O O
standard Reason 4 O O
care Reason 4 O O
in Reason 4 O O
the Reason 4 O O
management Reason 4 O O
of Reason 4 O O
asymptomatic, Reason 4 O O
mild Reason 4 O O
and Reason 4 O O
moderate Reason 4 O O
COVID-19 Reason 4 O O
to Reason 4 O O
improve Reason 4 O O
the Reason 4 O O
clinical Reason 4 O O
recovery Reason 4 O O
and Reason 4 O O
quality Reason 4 O O
of Reason 4 O O
life. Reason 4 O O
|INGREDIENTS||QUANTITY| Reason 4 O O
|Alstonia Reason 4 O O
scholaris Reason 4 O O
of Reason 4 O O
seed Reason 4 O O
(Kuberaksha)||Pulp-2 Reason 4 O O
parts| Reason 4 O O
The Reason 4 O O
above Reason 4 O O
ingredients Reason 4 O O
are Reason 4 O O
mixed Reason 4 O O
together, Reason 4 O O
made Reason 4 O O
into Reason 4 O O
tablets Reason 4 O O
of Reason 4 O O
500 Reason 4 O O
mg. Reason 4 O O
each Reason 4 O O
along Reason 4 O O
with Reason 4 O O
some Reason 4 O O
adhesives Reason 4 O O
like Reason 4 O O
starch Reason 4 O O
& Reason 4 O O
gum Reason 4 O O
acacia Reason 4 O O
etc. Reason 4 O O
It Reason 4 O O
can Reason 4 O O
be Reason 4 O O
taken Reason 4 O O
by Reason 4 O O
patients Reason 4 O O
at Reason 4 O O
any Reason 4 O O
stage Reason 4 O O
of Reason 4 O O
the Reason 4 O O
COVID-19 Reason 4 O O
disease. Reason 4 O O
However, O O O O
its O O O O
scientific O O O O
efficacy O O O O
was O O O O
scientifically O O O O
studied O O O O
in O O O O
asymptomatic, O O O O
mild O O O O
and O O O O
moderate O O O O
disease O O O O
without O O O O
risk O O O O
factors O O O O
for O O O O
poor O O O O
outcome O O O O
and O O O O
those O O O O
not O O O O
requiring O O O O
emergency O O O O
interventions O O O O
or O O O O
hospitalization O O O O
are O O O O
eligible O O O O
to O O O O
take O O O O
Ayush-64. O O O O
Mild O O O O
to O O O O
moderate O O O O
COVID-19 O O O O
cases O O O O
showing O O O O
initial O O O O
symptoms O O O O
like O O O O
fever, O O O O
malaise, O O O O
body O O O O
ache, O O O O
nasal O O O O
congestion, O O O O
nasal O O O O
discharge, O O O O
headache, O O O O
cough O O O O
etc. O O O O
and O O O O
asymptomatic O O O O
cases O O O O
of O O O O
COVID-19 O O O O
can O O O O
preferably O O O O
start O O O O
AYUSH-64 O O O O
within O O O O
7 O O O O
days O O O O
of O O O O
diagnosis O O O O
of O O O O
the O O O O
disease O O O O
through O O O O
RT-PCR O O O O
for O O O O
better O O O O
outcome. O O O O
AYUSH-64 O O O O
is O O O O
found O O O O
to O O O O
significantly O O O O
reduce O O O O
the O O O O
duration O O O O
for O O O O
clinical O O O O
recovery O O O O
in O O O O
terms O O O O
of O O O O
disease O O O O
symptoms O O O O
and O O O O
severity. O O O O
It O O O O
also O O O O
has O O O O
significant O O O O
beneficial O O O O
effects O O O O
on O O O O
general O O O O
health, O O O O
fatigue, O O O O
anxiety, O O O O
stress, O O O O
appetite, O O O O
general O O O O
wellbeing O O O O
and O O O O
sleep. O O O O
AYUSH-64 Reason 5 O O
is Reason 5 O O
a Reason 5 O O
poly Reason 5 O O
herbal Reason 5 O O
formulation Reason 5 O O
developed Reason 5 O O
in Reason 5 O O
compliance Reason 5 O O
to Reason 5 O O
all Reason 5 O O
regulatory Reason 5 O O
requirements Reason 5 O O
and Reason 5 O O
quality Reason 5 O O
and Reason 5 O O
pharmacopoeial Reason 5 O O
standards Reason 5 O O
by Reason 5 O O
the Reason 5 O O
Central Reason 5 O O
Council Reason 5 O O
for Reason 5 O O
Research Reason 5 O O
in Reason 5 O O
Ayurvedic Reason 5 O O
Sciences Reason 5 O O
(CCRAS) Reason 5 O O
the Reason 5 O O
apex Reason 5 O O
body Reason 5 O O
for Reason 5 O O
research Reason 5 O O
in Reason 5 O O
Ayurveda Reason 5 O O
under Reason 5 O O
the Reason 5 O O
Ministry Reason 5 O O
of Reason 5 O O
Ayush. Reason 5 O O
It O O O O
has O O O O
been O O O O
scientifically O O O O
found O O O O
to O O O O
be O O O O
useful O O O O
in O O O O
the O O O O
treatment O O O O
of O O O O
asymptomatic, O O O O
mild O O O O
and O O O O
moderate O O O O
COVID-19 O O O O
infection O O O O
as O O O O
an O O O O
adjunct O O O O
to O O O O
standard O O O O
care O O O O
through O O O O
robust O O O O
clinical O O O O
trials O O O O
conducted O O O O
in O O O O
the O O O O
country. O O O O
The O O O O
results O O O O
of O O O O
the O O O O
clinical O O O O
trials O O O O
demonstrated O O O O
that O O O O
AYUSH-64 O O O O
as O O O O
an O O O O
adjunct O O O O
to O O O O
standard O O O O
of O O O O
care O O O O
(SoC) O O O O
showed O O O O
clinically O O O O
significant O O O O
improvement O O O O
and O O O O
thus O O O O
lesser O O O O
period O O O O
of O O O O
hospitalization O O O O
as O O O O
compared O O O O
to O O O O
SoC O O O O
alone. O O O O
The O O O O
dose O O O O
for O O O O
asymptomatic O O O O
COVID-19 O O O O
case: O O O O
2 O O O O
tablets O O O O
of O O O O
500 O O O O
mg O O O O
twice O O O O
daily O O O O
one O O O O
hour O O O O
after O O O O
meals O O O O
with O O O O
warm O O O O
water O O O O
for O O O O
14 O O O O
days. O O O O
The O O O O
dose O O O O
for O O O O
mild O O O O
to O O O O
moderate O O O O
COVID-19 O O O O
cases: O O O O
2 O O O O
tablets O O O O
of O O O O
500 O O O O
mg O O O O
thrice O O O O
daily O O O O
one O O O O
hour O O O O
after O O O O
meals O O O O
with O O O O
warm O O O O
water O O O O
for O O O O
14 O O O O
days. O O O O
Loose O O O O
motions, O O O O
can O O O O
occur O O O O
in O O O O
some O O O O
patients, O O O O
which O O O O
is O O O O
self-limiting O O O O
and O O O O
does O O O O
not O O O O
require O O O O
any O O O O
medical O O O O
intervention. O O O O
It O O O O
may O O O O
be O O O O
used O O O O
for O O O O
prophylaxis O O O O
also, O O O O
in O O O O
a O O O O
dose O O O O
of O O O O
2 O O O O
tablets O O O O
of O O O O
500 O O O O
mg O O O O
twice O O O O
daily, O O O O
but O O O O
its O O O O
efficacy O O O O
as O O O O
a O O O O
prophylactic O O O O
agent O O O O
has O O O O
not O O O O
been O O O O
demonstrated O O O O
through O O O O
clinical O O O O
studies. O O O O
But O O O O
if O O O O
a O O O O
person O O O O
is O O O O
exposed O O O O
to O O O O
a O O O O
COVID-19 O O O O
case, O O O O
AYUSH-64 O O O O
can O O O O
be O O O O
taken O O O O
when O O O O
symptoms O O O O
appear. O O O O
However, Reason 3 O O
the Reason 3 O O
person Reason 3 O O
should Reason 3 O O
get Reason 3 O O
tested Reason 3 O O
for Reason 3 O O
COVID-19 Reason 3 O O
through Reason 3 O O
RT-PCR Reason 3 O O
or Reason 3 O O
Rapid Reason 3 O O
antigen Reason 3 O O
test Reason 3 O O
and Reason 3 O O
should Reason 3 O O
follow Reason 3 O O
SoC. Reason 3 O O
It Reason 3 O O
can Reason 3 O O
be Reason 3 O O
taken Reason 3 O O
as Reason 3 O O
a Reason 3 O O
standalone Reason 3 O O
treatment Reason 3 O O
in Reason 3 O O
mild Reason 3 O O
cases, Reason 3 O O
under Reason 3 O O
the Reason 3 O O
strict Reason 3 O O
supervision Reason 3 O O
of Reason 3 O O
an Reason 3 O O
Ayurvedic Reason 3 O O
physician; Reason 3 O O
provided Reason 3 O O
there Reason 3 O O
is Reason 3 O O
availability Reason 3 O O
of Reason 3 O O
appropriate Reason 3 O O
referral Reason 3 O O
facilities. Reason 3 O O
However, Reason 3 O O
it Reason 3 O O
is Reason 3 O O
advised Reason 3 O O
that Reason 3 O O
AYUSH-64 Reason 3 O O
should Reason 3 O O
be Reason 3 O O
taken Reason 3 O O
as Reason 3 O O
adjunct Reason 3 O O
to Reason 3 O O
the Reason 3 O O
SoC Reason 3 O O
in Reason 3 O O
mild Reason 3 O O
to Reason 3 O O
moderate Reason 3 O O
disease, Reason 3 O O
when Reason 3 O O
the Reason 3 O O
patient Reason 3 O O
is Reason 3 O O
under Reason 3 O O
home Reason 3 O O
isolation. Reason 3 O O
AYUSH- O O O O
64, O O O O
shall O O O O
only O O O O
be O O O O
used O O O O
as O O O O
per O O O O
the O O O O
advice O O O O
of O O O O
a O O O O
qualified O O O O
Ayush O O O O
practitioner. O O O O
AYUSH-64 O O O O
can O O O O
be O O O O
taken O O O O
for O O O O
a O O O O
minimum O O O O
period O O O O
of O O O O
14 O O O O
days. O O O O
However, O O O O
if O O O O
required, O O O O
it O O O O
can O O O O
be O O O O
taken O O O O
up O O O O
to O O O O
12 O O O O
weeks, O O O O
as O O O O
per O O O O
the O O O O
advice O O O O
of O O O O
a O O O O
qualified O O O O
Ayush O O O O
practitioner. O O O O
It O O O O
has O O O O
been O O O O
scientifically O O O O
proven O O O O
to O O O O
be O O O O
safe O O O O
up O O O O
to O O O O
12 O O O O
weeks, O O O O
through O O O O
clinical O O O O
studies. O O O O
It O O O O
can O O O O
be O O O O
taken O O O O
with O O O O
warm O O O O
water, O O O O
preferably O O O O
one O O O O
hour O O O O
after O O O O
the O O O O
food. O O O O
Patients O O O O
with O O O O
co-morbidities O O O O
like O O O O
hypertension, O O O O
diabetes O O O O
etc., O O O O
can O O O O
take O O O O
AYUSH-64 O O O O
for O O O O
asymptomatic, O O O O
mild O O O O
to O O O O
moderate O O O O
disease O O O O
and O O O O
are O O O O
advised O O O O
not O O O O
to O O O O
discontinue O O O O
their O O O O
respective O O O O
medications. O O O O
Yes. Reason 3 O O
If Reason 3 O O
a Reason 3 O O
person Reason 3 O O
gets Reason 3 O O
infected Reason 3 O O
even Reason 3 O O
after Reason 3 O O
vaccination, Reason 3 O O
AYUSH-64 Reason 3 O O
can Reason 3 O O
be Reason 3 O O
taken Reason 3 O O
within Reason 3 O O
7 Reason 3 O O
days Reason 3 O O
of Reason 3 O O
testing Reason 3 O O
RT-PCR Reason 3 O O
positive Reason 3 O O
for Reason 3 O O
SARS Reason 3 O O
CoV-2, Reason 3 O O
in Reason 3 O O
consultation Reason 3 O O
with Reason 3 O O
an Reason 3 O O
Ayush Reason 3 O O
Physician. Reason 3 O O
However, Reason 3 O O
evidence Reason 3 O O
in Reason 3 O O
favor Reason 3 O O
of Reason 3 O O
it Reason 3 O O
has Reason 3 O O
not Reason 3 O O
been Reason 3 O O
elicited Reason 3 O O
through Reason 3 O O
scientific Reason 3 O O
studies. Reason 3 O O
The O O O O
safety O O O O
of O O O O
AYUSH-64 O O O O
is O O O O
not O O O O
established O O O O
through O O O O
scientific O O O O
studies O O O O
in O O O O
pregnant O O O O
and O O O O
lactating O O O O
women. O O O O
It O O O O
is O O O O
available O O O O
in O O O O
market O O O O
and O O O O
can O O O O
be O O O O
purchased O O O O
from O O O O
Ayurvedic O O O O
pharmacies. O O O O
However, O O O O
it O O O O
should O O O O
be O O O O
ensured O O O O
that, O O O O
it O O O O
should O O O O
not O O O O
be O O O O
used O O O O
as O O O O
an O O O O
over O O O O
the O O O O
counter O O O O
prescription O O O O
(OTC) O O O O
and O O O O
shall O O O O
only O O O O
be O O O O
used O O O O
under O O O O
the O O O O
supervision O O O O
of O O O O
Ayurvedic O O O O
physicians. O O O O
There O O O O
are O O O O
no O O O O
special O O O O
precautions O O O O
to O O O O
be O O O O
followed O O O O
while O O O O
using O O O O
AYUSH-64. O O O O
However, O O O O
one O O O O
must O O O O
follow O O O O
all O O O O
the O O O O
COVID-19 O O O O
related O O O O
guidelines O O O O
given O O O O
by O O O O
Ministry O O O O
of O O O O
Ayush O O O O
and O O O O
Ministry O O O O
of O O O O
Health O O O O
and O O O O
Family O O O O
Welfare, O O O O
Government O O O O
of O O O O
India. O O O O
MRP: O O O O
Rs. O O O O
450/- O O O O
for O O O O
60 O O O O
Tablets O O O O
